MX2021012708A - Formulaciones novedosas que comprenden melflufen. - Google Patents
Formulaciones novedosas que comprenden melflufen.Info
- Publication number
- MX2021012708A MX2021012708A MX2021012708A MX2021012708A MX2021012708A MX 2021012708 A MX2021012708 A MX 2021012708A MX 2021012708 A MX2021012708 A MX 2021012708A MX 2021012708 A MX2021012708 A MX 2021012708A MX 2021012708 A MX2021012708 A MX 2021012708A
- Authority
- MX
- Mexico
- Prior art keywords
- melflufen
- optionally
- iii
- salt
- novel formulations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Emergency Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La invención proporciona una formulación farmacéutica que comprende (o consiste esencialmente de) los siguientes componentes: i) melflufén, o una sal de éste; ii) propilenglicol; iii) de manera opcional, uno o más solventes acuosos fisiológicamente aceptables; y iv) de manera opcional, uno o más agentes terapéuticos adicionales; o una formulación farmacéutica que comprende (o consiste esencialmente de) los siguientes componentes: i) melflufén, o una sal de éste; ii) polietilenglicol; iii) de manera opcional, uno o más solventes acuosos fisiológicamente aceptables; y iv) de manera opcional, uno o más agentes terapéuticos; la invención también proporciona métodos para preparar las formulaciones farmacéuticas de la invención, kits y usos de las formulaciones farmacéuticas de la invención.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1905477.4A GB201905477D0 (en) | 2019-04-17 | 2019-04-17 | Novel formulations |
| PCT/EP2020/060900 WO2020212594A1 (en) | 2019-04-17 | 2020-04-17 | Novel formulations comprising melflufen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021012708A true MX2021012708A (es) | 2021-11-12 |
Family
ID=66810019
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021012708A MX2021012708A (es) | 2019-04-17 | 2020-04-17 | Formulaciones novedosas que comprenden melflufen. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20220184021A1 (es) |
| EP (1) | EP3956032A1 (es) |
| JP (1) | JP2022529915A (es) |
| KR (1) | KR20220002901A (es) |
| CN (1) | CN114040798A (es) |
| AU (1) | AU2020259142A1 (es) |
| BR (1) | BR112021018707A2 (es) |
| CA (1) | CA3133886A1 (es) |
| EA (1) | EA202192845A1 (es) |
| GB (1) | GB201905477D0 (es) |
| IL (1) | IL287224A (es) |
| MX (1) | MX2021012708A (es) |
| SG (1) | SG11202110605SA (es) |
| WO (1) | WO2020212594A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202109896D0 (en) | 2021-07-08 | 2021-08-25 | Oncopeptides Ab | Novel treatments |
| WO2023281007A1 (en) | 2021-07-08 | 2023-01-12 | Oncopeptides Ab | Melflufen for use in the treatment of multiple myeloma |
| GB202109894D0 (en) | 2021-07-08 | 2021-08-25 | Oncopeptides Ab | Novel treatments |
| GB202109895D0 (en) | 2021-07-08 | 2021-08-25 | Oncopeptides Ab | Novel treatments |
| GB202204171D0 (en) | 2022-03-24 | 2022-05-11 | Oncopeptides Ab | Novel formulations |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0002202D0 (sv) | 2000-06-13 | 2000-06-13 | Karolinska Innovations Ab | New peptides |
| WO2011078782A1 (en) * | 2009-12-22 | 2011-06-30 | Oncopeptides Ab | A composition comprising of melphalan derivatives and gemcitabine or etoposide useful in the treatment of cancer |
| PT3656393T (pt) * | 2011-04-28 | 2022-11-03 | Oncopeptides Ab | Preparação liofilizada de dipéptidos citotóxicos |
| CA2889753C (en) | 2012-10-26 | 2021-03-02 | Oncopeptides Ab | Lyophilized preparations of melphalan flufenamide |
| GB201521217D0 (en) * | 2015-12-01 | 2016-01-13 | Oncopeptides Ab | Dosage regimens |
| KR20200136997A (ko) * | 2018-03-29 | 2020-12-08 | 프로젝트 파마슈틱스 게엠베하 | 액체 약학적 제형 |
| SG11202103726RA (en) * | 2018-10-18 | 2021-05-28 | Oncopeptides Ab | Compounds containing deuterium |
-
2019
- 2019-04-17 GB GBGB1905477.4A patent/GB201905477D0/en not_active Ceased
-
2020
- 2020-04-17 EP EP20722234.0A patent/EP3956032A1/en active Pending
- 2020-04-17 WO PCT/EP2020/060900 patent/WO2020212594A1/en unknown
- 2020-04-17 CN CN202080029162.1A patent/CN114040798A/zh active Pending
- 2020-04-17 SG SG11202110605SA patent/SG11202110605SA/en unknown
- 2020-04-17 EA EA202192845A patent/EA202192845A1/ru unknown
- 2020-04-17 JP JP2021560977A patent/JP2022529915A/ja active Pending
- 2020-04-17 MX MX2021012708A patent/MX2021012708A/es unknown
- 2020-04-17 CA CA3133886A patent/CA3133886A1/en active Pending
- 2020-04-17 BR BR112021018707A patent/BR112021018707A2/pt unknown
- 2020-04-17 KR KR1020217033592A patent/KR20220002901A/ko unknown
- 2020-04-17 US US17/603,762 patent/US20220184021A1/en active Pending
- 2020-04-17 AU AU2020259142A patent/AU2020259142A1/en active Pending
-
2021
- 2021-10-13 IL IL287224A patent/IL287224A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3133886A1 (en) | 2020-10-22 |
| US20220184021A1 (en) | 2022-06-16 |
| BR112021018707A2 (pt) | 2021-11-23 |
| AU2020259142A1 (en) | 2021-11-25 |
| EA202192845A1 (ru) | 2022-01-26 |
| KR20220002901A (ko) | 2022-01-07 |
| WO2020212594A1 (en) | 2020-10-22 |
| SG11202110605SA (en) | 2021-10-28 |
| GB201905477D0 (en) | 2019-05-29 |
| EP3956032A1 (en) | 2022-02-23 |
| IL287224A (en) | 2021-12-01 |
| JP2022529915A (ja) | 2022-06-27 |
| CN114040798A (zh) | 2022-02-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021012708A (es) | Formulaciones novedosas que comprenden melflufen. | |
| MY192084A (en) | Pyrazolo-heteroaryl derivative, preparation method and medical use thereof | |
| CA3057882A1 (en) | Substituted dihydro-spiro-napthalene-oxa derivatives and pharmaceutical compositions thereof useful as inhibitors of mcl-1 protein | |
| EP3690050A4 (en) | MULTISPECIFIC ANTIGEN-BINDING MOLECULE HAVING SUBSTITUTION ACTIVITY FOR THE FUNCTION OF BLOOD COAGULATION FACTOR VIII COFACTOR (FVIII), AND PHARMACEUTICAL FORMULATION CONTAINING THE SAME MOLECULE AS ACTIVE PRINCIPLE | |
| AU2016343803A8 (en) | Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids | |
| WO2015184127A3 (en) | Stable cannabinoid formulations | |
| CR20200334A (es) | Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas | |
| WO2020257549A3 (en) | Compounds for treatment of pd-l1 diseases | |
| MY187047A (en) | Selective pyy compounds and uses thereof | |
| PH12021550992A1 (en) | Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as atr kinase inhibitors | |
| WO2017100700A3 (en) | Peptides for renal therapy | |
| PH12021551256A1 (en) | Pantetheine derivatives and uses thereof | |
| WO2019165043A3 (en) | Indane-amines as pd-l1 antagonists | |
| MX2021009439A (es) | Derivados de imidazo [2,1-f] [1,2,4] triazin-4-amina como agonista de tlr7. | |
| EP4327877A3 (en) | Dual atm and dna-pk inhibitors for use in anti-tumor therapy | |
| MX2020011873A (es) | Nuevos derivados de quinolina. | |
| MX2020008323A (es) | Composiciones farmacéuticas hipertónicas que contienen un agente quimioprotector antiplatino. | |
| MX2020013785A (es) | Derivado de la pirido-pirimidina, metodo de preparacion del mismo y uso medico del mismo. | |
| CR20220216A (es) | Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1 | |
| MX2022006519A (es) | Medicamento conjugado con polietilenglicol, metodo de preparacion del mismo y uso del mismo. | |
| GEP20247585B (en) | Furoindazole derivatives | |
| ZA202006071B (en) | Antiproliferation compounds and uses thereof | |
| MX2020011453A (es) | Combinaciones para tratar el cancer. | |
| MX2021007247A (es) | Derivados de rapamicina. | |
| JOP20210230A1 (ar) | صياغات صيدلانية |